{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:12Z","timestamp":1792601352062,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To summarize effects of intravenous bisphosphonates (IVBP) in patients with symptomatic knee OA and bone marrow lesions (BMLs), using a meta-analysis of randomized controlled trials (RCTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Literature databases were searched for placebo-controlled RCTs of IVBPs for knee OA from inception, and included validated pain and function scales, BML size and incidence of adverse events. Efficacy was compared using standardized mean differences (SMD) and risk ratios (RR) with fixed-effect or random-effects models. Methodological quality was assessed using the Cochrane risk of bias tool, heterogeneity was assessed by I2 statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 428 patients in four RCTs of 2\u201324\u2009months duration; most patients (84%) received zoledronic acid (ZA). Risk of bias was low-moderate. IVBP had large effect sizes on pain within 3\u2009months [SMD = \u22122.33 (95% CI: \u22123.02, \u22121.65)] mainly driven by neridronate (resulting in substantial heterogeneity, I2 = 92%) with no effect for ZA alone. Differences in knee function were statistically significant at 3\u2009months [SMD = \u22120.22 (\u22120.43, \u22120.01), I2 = 0.2%]. Effect sizes for pain did not reach statistical significance at any other time point. IVBPs improved a semi-quantitative measure of BML size within 6\u2009months [SMD = \u22120.52 (\u22120.89, \u22120.14), I2 = 0%] but not at 12\u2009months or two years. Adverse events [RR\u2009=\u20091.19 (1.00, 1.41) I2 = 52%], occurred more frequently with IVBP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ZA has no effect on knee pain, possibly a short-term effect on BML size and higher rates of adverse events. Neridronate may improve pain in the short term, but this is based on a single trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab786","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:03:13Z","timestamp":1634688193000},"page":"2235-2242","source":"Crossref","is-referenced-by-count":18,"title":["Intravenous bisphosphonates do not improve knee pain or bone marrow lesions in people with knee osteoarthritis: a meta-analysis"],"prefix":"10.1093","volume":"61","author":[{"given":"Xu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University , Hefei, China"},{"name":"Menzies Institute for Medical Research, University of Tasmania , Tasmania, Australia and"},{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University , Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6481-704X","authenticated-orcid":false,"given":"Guoqi","family":"Cai","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania , Tasmania, Australia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9814-0006","authenticated-orcid":false,"given":"Graeme","family":"Jones","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania , Tasmania, Australia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L","family":"Laslett","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania , Tasmania, Australia and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"key":"2022060107541032300_keab786-B1","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","article-title":"Osteoarthritis: an update with relevance for clinical practice","volume":"377","author":"Bijlsma","year":"2011","journal-title":"Lancet"},{"key":"2022060107541032300_keab786-B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bmb\/lds038","article-title":"Epidemiology and burden of osteoarthritis","volume":"105","author":"Litwic","year":"2013","journal-title":"Br Med Bull"},{"key":"2022060107541032300_keab786-B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/41.S1.3","article-title":"The prevalence and burden of arthritis","volume":"41(Supp 1","author":"Reginster","year":"2002","journal-title":"Rheumatology"},{"key":"2022060107541032300_keab786-B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2013.07.003","article-title":"Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)","volume":"43","author":"Hiligsmann","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2022060107541032300_keab786-B5","first-page":"646","article-title":"Burden of major musculoskeletal conditions","volume":"81","author":"Woolf","year":"2003","journal-title":"Bull World Health Organ"},{"key":"2022060107541032300_keab786-B6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41584-020-00523-9","article-title":"Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines","volume":"17","author":"Arden","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2022060107541032300_keab786-B7","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2011-200970","article-title":"Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial","volume":"71","author":"Laslett","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022060107541032300_keab786-B8","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/rheumatology\/kev123","article-title":"Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study","volume":"54","author":"Varenna","year":"2015","journal-title":"Rheumatology"},{"key":"2022060107541032300_keab786-B9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00296-014-3100-5","article-title":"Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial","volume":"35","author":"Rossini","year":"2015","journal-title":"Rheumatol Int"},{"key":"2022060107541032300_keab786-B10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.joca.2018.01.005","article-title":"Bisphosphonates intake and its association with changes of periarticular bone area and three-dimensional shape: data from the Osteoarthritis Initiative (OAI)","volume":"26","author":"Haj-Mirzaian","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"2022060107541032300_keab786-B11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0002-9343(00)00541-6","article-title":"Osteoporotic fractures: ignorance is bliss?","volume":"109","author":"Bauer","year":"2000","journal-title":"Am J Med"},{"key":"2022060107541032300_keab786-B12","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060107541032300_keab786-B13","doi-asserted-by":"crossref","first-page":"e72714","DOI":"10.1371\/journal.pone.0072714","article-title":"Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review","volume":"8","author":"Davis","year":"2013","journal-title":"PLoS One"},{"key":"2022060107541032300_keab786-B14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2014.06.009","article-title":"Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression","volume":"66","author":"Siebelt","year":"2014","journal-title":"Bone"},{"key":"2022060107541032300_keab786-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-015-0546-0","article-title":"Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice","volume":"17","author":"Khorasani","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022060107541032300_keab786-B16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.joca.2012.03.021","article-title":"Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation","volume":"20","author":"Panahifar","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"2022060107541032300_keab786-B17","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar3373","article-title":"Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model","volume":"13","author":"Moreau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2022060107541032300_keab786-B18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/annrheumdis-2012-202989","article-title":"Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative","volume":"73","author":"Laslett","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022060107541032300_keab786-B19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/annrheumdis-2017-211811","article-title":"Effect of bisphosphonates on knee replacement surgery","volume":"77","author":"Neogi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022060107541032300_keab786-B20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2106\/JBJS.16.00385","article-title":"Bisphosphonate use and the risk of undergoing total knee arthroplasty in osteoporotic patients with osteoarthritis: a nationwide cohort study in Taiwan","volume":"99","author":"Fu","year":"2017","journal-title":"J Bone Joint Surg Am"},{"key":"2022060107541032300_keab786-B21","first-page":"221","article-title":"The effect of hydroxychloroquine on symptoms of knee osteoarthritis: a double-blind randomized controlled clinical trial","volume":"38","author":"Jokar","year":"2013","journal-title":"Iran J Med Sci"},{"key":"2022060107541032300_keab786-B22","doi-asserted-by":"crossref","first-page":"R625","DOI":"10.1186\/ar1716","article-title":"Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173","volume":"7","author":"Spector","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2022060107541032300_keab786-B23","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/art.22160","article-title":"Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study","volume":"54","author":"Bingham","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"2022060107541032300_keab786-B24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.joca.2017.11.013","article-title":"Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials","volume":"26","author":"Vaysbrot","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"2022060107541032300_keab786-B25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00774-019-01005-z","article-title":"Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study","volume":"37","author":"Hagino","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"2022060107541032300_keab786-B26","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.joca.2016.05.009","article-title":"Bone marrow lesions in hip osteoarthritis are characterized by increased bone turnover and enhanced angiogenesis","volume":"24","author":"Shabestari","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"2022060107541032300_keab786-B27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2020.2938","article-title":"Effect of intravenous zoledronic acid on tibiofemoral cartilage volume among patients with knee osteoarthritis with bone marrow lesions: a randomized clinical trial","volume":"323","author":"Cai","year":"2020","journal-title":"JAMA"},{"key":"2022060107541032300_keab786-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2022060107541032300_keab786-B29","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2022060107541032300_keab786-B30","author":"Higgins","year":"2011"},{"key":"2022060107541032300_keab786-B31","doi-asserted-by":"crossref","first-page":"1759720x19880054","DOI":"10.1177\/1759720X19880054","article-title":"Zoledronic acid plus methylprednisolone versus zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial","volume":"11","author":"Cai","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab786\/41115999\/keab786.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2235\/43891541\/keab786.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2235\/43891541\/keab786.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:55:18Z","timestamp":1654070118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2235\/6409204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,23]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab786","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,23]]}}}